Syros Pharmaceuticals, Inc. (SYRS) Earnings History
Net Loss11 years of earnings data (2013–2023) · Currently unprofitable on a TTM basis
Loading earnings history...
Syros Pharmaceuticals, Inc. (SYRS) Earnings Overview
As of June 23, 2026, Syros Pharmaceuticals, Inc. (SYRS) reported trailing twelve-month net income of -$98M, reflecting +22.4% year-over-year growth. The company earned $-2.49 per diluted share over the past four quarters, with a net profit margin of -1656.3%.
Looking at the long-term picture, SYRS's historical earnings data spans multiple years. The company achieved its highest annual net income of -$9M in fiscal 2013.
Syros Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KYMR (-$315M net income, -794.4% margin), ARVN (-$221M net income, -30.8% margin), IMVT (-$506M net income), SYRS has room to improve margins relative to the peer group. Compare SYRS vs KYMR →
SYRS Earnings vs Peers
Earnings metrics vs comparable public companies
SYRS Historical Earnings Data (2013–2023)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2023 | -$165M | -73.9% | -$129M | $-5.81 | -1656.3% | -1298.2% |
| 2022 | -$95M | -9.4% | -$136M | $-7.49 | -636.1% | -913.1% |
| 2021 | -$87M | -3.0% | -$99M | $-13.84 | -368.5% | -423.3% |
| 2020 | -$84M | -11.4% | -$82M | $-18.25 | -556.8% | -545.3% |
| 2019 | -$75M | -21.1% | -$78M | $-18.76 | -3806.2% | -3922.4% |
| 2018 | -$62M | -15.3% | -$64M | $-19.07 | -3038.0% | -3136.4% |
| 2017 | -$54M | -13.1% | -$55M | $-21.26 | -4905.5% | -4966.9% |
| 2016 | -$48M | -60.1% | -$48M | $-37.60 | -15060.9% | -15130.3% |
| 2015 | -$30M | -122.0% | -$30M | $-120.45 | -9406.3% | -9406.9% |
| 2014 | -$13M | -45.1% | -$13M | $-54.25 | - | - |
| 2013 | -$9M | - | -$9M | $-84.47 | - | - |
Download Data
Export SYRS earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
13+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SYRS — Frequently Asked Questions
Quick answers to the most common questions about buying SYRS stock.
What is SYRS earnings per share (EPS)?
SYRS trailing twelve-month (TTM) diluted EPS is $-2.49, reflecting +22.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2013 to 2023 is available in the table on this page.
What is Syros Pharmaceuticals, Inc.'s net income?
Syros Pharmaceuticals, Inc. (SYRS) trailing twelve-month net income is $-98M as of 2023. Earnings grew +22.4% year-over-year.
Is SYRS profitable?
SYRS is not currently profitable on a TTM basis, reporting a net loss of $-98M. Net margin is -1656.3%. Investors should monitor for a return to profitability.
What is SYRS's earnings growth rate?
SYRS compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2013 to 2023.
What are SYRS's profit margins?
Syros Pharmaceuticals, Inc. net profit margin is -1656.3%, operating margin is -1298.2%, and gross margin is +77.3%. Below-average margins reflect competitive or cost pressures. Return on Equity is -227.9%.
Is SYRS growing earnings?
Yes, SYRS earnings are accelerating — EPS growth of +22.4% exceeds the 5-year CAGR of N/A. TTM net income reached $-98M. Earnings momentum is strengthening.
What was SYRS's best earnings year?
Syros Pharmaceuticals, Inc.'s highest annual net income on record is $-9M, achieved in fiscal year 2013. Earnings history on this page spans 2013 to 2023 and includes all annual and quarterly figures.
What were SYRS's earnings last quarter?
SYRS's most recent reported quarter was Q3 2024. Net income was $-6M with diluted EPS of $-0.16. For a full breakdown of all quarters, see the quarterly earnings table on this page.